Cambrex Corporation operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Cambrex with three other
companies in this sector in the United States:
Swedish Orphan Biovitrum AB (publ)
sales of $381.47 million
of which 25%
was Core Products/Kineret),
Opko Health Incorporation
of which 67%
was Diagnostics), and
Lannett Company, Inc.
of which 100%
was Generic Pharmaceutical).
Cambrex reported sales of $433.93 million
December of 2015.
increase of 15.9%
versus 2014, when the company's sales were $374.43 million.
Sales at Cambrex have increased during each of the previous five years
(and since 2010, sales have increased a total of 93%).